Notch Therapeutics

Notch has developed a proprietary platform with the potential to fully enable best-in-class commercial manufacturing of stem-cell derived T cells.  As current T cell therapies are limited by the use of a patient’s own cells, Notch T cells could replace existing standard-of-care therapies and pave a path to novel therapeutics to address unmet need.

In February 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem cell-derived cancer immunotherapies: https://notchtx.com/